Chronic haloperidol treatment impairs glutamate transport in the rat striatum

European Journal of Pharmacology

Volumn 382, Issue 2, 1999, Pages 139-142

  De Souza, Ian E J ^a   McBean, Gethin J ^b   Meredith, Gloria E ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Glutamate; Haloperidol; Striatum; Synaptosome; Transport

Indexed keywords

DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; HALOPERIDOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RECEPTOR BLOCKING; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ANIMALS; ASPARTIC ACID; BIOLOGICAL TRANSPORT; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; GLUTAMIC ACID; HALOPERIDOL; MALE; RATS; RATS, WISTAR; SYNAPTOSOMES; TRITIUM;

EID: 0032831787     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00589-0     Document Type: Article

References (26)

1. Andreassen O.A., Jørgensen H.A. GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats. Psychopharmacology. 116:1994;517-522.
2. Bardgett M.E., Wrona C.T., Newcomer J.W., Csernansky J.G. Subcortical excitatory amino acid levels after acute and subchronic administration of typical and atypical neuroleptics. Eur. J. Pharmacol. 230:1993;245-250.
3. Berman S.B., Hastings T.A. Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species. J. Neurochem. 69:1997;1185-1195.
4. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 196:1976;326-328.
5. Crow T.J., Deakin J.F., Longden A. Proceedings: do anti-psychotic drugs act by dopamine receptor blockade in the nucleus accumbens. Br. J. Pharmacol. 113:1975;536-540.
6. Davies L.P., Johnston G.A.R. Uptake and release of D- and L-aspartate by rat brain slices. J. Neurochem. 26:1976;1007-1014.
7. De Keyser J. Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin. Neuropharm. 14:1991;562-565.
8. Deutch A.Y., Lee M.C., Iadarola M.J. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol. Cell. Neurosci. 3:1992;332-341.
9. 1 fraction: homogeneity and morphology of subcellular fractions. Brain Res. 441:1988;59-71.
10. Fonnum F. Glutamate: a neurotransmitter in the mammalian brain. J. Neurochem. 42:1984;1-11.
11. Fyske E.M., Iversen E.G., Fonnum F. Inhibition of glutamate uptake into synaptic vesicles. Neurosci. Lett. 135:1992;125-128.
12. Kerkerian L., Dusticier N., Nieoullon A. Modulatory effect of dopamine on high-affinity glutamate uptake in the rat striatum. J. Neurochem. 48:1987;1301-1306.
13. Markwell M., Haas S.M., Bieber L., Tolbert T. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87:1978;206-210.
14. McBean G.J. Inhibition of the glutamate transporter and glial enzymes in the rat striatum by the gliotoxin, αaminodipate. Br. J. Pharmacol. 113:1994;536-540.
15. Meshul C.K., Andreassen O.A., Allen C., Jørgensen H.A. Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol. Psychopharmacology. 125:1996;238-247.
16. Olney J.W. Excitotoxic amino acids and neuropsychiatric disorders. Annu. Rev. Pharmacol. Toxicol. 30:1990;47-71.
17. Perry T.L., Hansen S., Kish S.J. Effects of chronic administration of antipsychotic drugs on GABA and other amino acids in the mesolimbic area of rat brain. Life Sci. 24:1979;283-288.
18. Rothstein J.D., Dykes-Hoberg M., Pardo C.A., Bristol L.A., Jin L., Kuncl R.W., Kanai Y., Hediger M.A., Wang Y., Schielke J.P., Welty D.F. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 16:1996;675-686.
19. Santiago M., Westerink B.H.C. The regulation of dopamine release from nigrostriatal neurons in conscious rats: the role of somatodendritic autoreceptors. Eur. J. Pharmacol. 204:1991;79-85.
20. Schneider J.S., Wade T., Lidsky T.I. Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum. NeuroReport. 9:1998;133-136.
21. See R.E., Chapman M.A. Chronic haloperidol, but not clozapine, produce altered oral movements and increased extracellular glutamate in rats. Eur. J. Pharmacol. 263:1994;269-276.
22. See R.E., Lynch A.M. Chronic haloperidol potentiates stimulated glutamate release in caudate putamen but not prefrontal cortex. NeuroReport. 6:1995;1795-1798.
23. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 188:1975;1217-1219.
24. Takahashi M., Billups B., Rossi D., Sarantis M., Hamann M., Attwell A. The role of glutamate transporters in glutamate homeostasis in the brain. J. Exp. Biol. 200:1997;401-409.
25. Wright A.M., Bempong J., Kirby M.L., Barlow R.L., Bloomquist J.R. Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res. 788:1998;215-222.
26. Yamamoto B.K., Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14:1994;4159-4166.